TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Ascentage Pharma
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

Ascentage Pharma presented four-year follow-up data for Olverembatinib, demonstrating improved disease control and safety in treating chronic myeloid leukemia patients resistant to existing tyrosine kinase inhibitors.

Insights
GOOGL   neutral

Mentioned as a technology partner for SecOps platform, with no significant positive or negative implications


IVBIY   neutral

Mentioned as joint commercialization partner for Olverembatinib in China with no specific performance details